

ASX/MEDIA RELEASE

10 September 2018

Sirtex Shareholders Vote in Favour of Scheme

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) today announces that shareholders have voted in favour of the proposed acquisition of Sirtex Medical by Grand Pharma Sphere (Australia Bidco) Pty Limited (**Bidco**), an entity owned by CDH Genetech Limited and China Grand Pharmaceutical and Healthcare Holdings Limited (collectively, **the Bidders**) via a scheme of arrangement (**Scheme**) at the scheme meeting (**Scheme Meeting**) held today at 10:00 am at the Royal Automobile Club of Australia, 89 Macquarie Street, Sydney.

Sirtex advises that the resolution to approve the Scheme as set out in the Notice of Scheme Meeting dated 1 August 2018, was passed by the requisite majorities of Sirtex Shareholders at the Scheme Meeting, being:

- a majority in number (more than 50%) of Sirtex shareholders present and voting at the Scheme Meeting (either in person or by proxy, attorney or, in the case of corporate Sirtex shareholders, body corporate representative); and
- at least 75% of the total number of votes cast on the Scheme Resolution at the Scheme Meeting.

The resolution was decided by a poll, the results of which are provided as an attachment to this release.

Sirtex has applied to the Federal Court of Australia (**Court**) to approve the Scheme at a hearing scheduled at 10:15am on Wednesday, 12 September 2018. Sirtex will provide a further update after that hearing.

- ENDS -

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 92,000 doses supplied and administered at over 1,230 medical centres in more than 40 countries.

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited

Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:


Dr Tom Duthy Global Head of Investor Relations & Corporate Development Sirtex Medical Limited Phone: +61 (0) 2 9964 8427

Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit: http://www.sirtex.com/au/investors/email-alerts/

Follow us on Twitter: **@sirtexmedical**Visit us on LinkedIn: **Sirtex Medical Limited**

SIRTEX MEDICAL LIMITED





Printed: 10/09/2018 10:33:57AM

SCHEME MEETING Monday, 10 September, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
Resolution	Votes <i>For</i>	Votes Against	Votes Discretionary	Votes <i>Abstain</i>	For	Against	Abstain **
That, pursuant to and in accordance with the provisions of section 411 of the Corporations Act 2001 (Cth), the scheme of arrangement proposed between Sirtex Medical Limited and the holders of its ordinary shares, as contained in and more particularly described in the scheme booklet of which the notice convening this meeting forms part, is approved, with or without alterations or conditions as approved by the Federal Court of Australia to which Sirtex Medical Limited, CDH Genetech Limited and China Grand Pharmaceutical and Healthcare Holdings Limited agree.1	25,974,529	80,622	309,469	27,389	26,311,219 99.69% Holders 1,203 97.25%	80,922 0.31% Holders 34 2.75%	38,058 Holders 22

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item